甘精胰岛素与西格列汀联用治疗老年2型糖尿病临床观察  

Efficacy and safety of insulin glargine in combination with sitagliptin on elderly patients with type 2 diabetes

作　　者：于湛[1] 田力[1] 

机构地区：[1]大连医科大学附属第一医院药学部,大连116011

出　　处：《实用药物与临床》2013年第2期159-160,共2页Practical Pharmacy and Clinical Remedies

摘　　要：目的探讨甘精胰岛素联用西格列汀治疗高龄2型糖尿病的疗效及安全性。方法将78例60岁以上的2型糖尿病患者随机分成甘精胰岛素联用西格列汀组(G组)40例和生物合成预混30/70人胰岛素组(N组)38例,根据血糖情况调整用药剂量,治疗12周后比较两组的空腹血糖、餐后2 h血糖、糖化血红蛋白(HbA1c)、低血糖发生率及体重指数(BMI)。结果 G组在空腹2 h血糖和低血糖发生率方面均低于N组,两组比较差异有统计学意义(P<0.05);在餐后血糖、HbA1c和BMI方面两组比较差异无统计学意义(P>0.05)。结论甘精胰岛素与西格列汀联用对老年2型糖尿病患者是一种安全、有效且方便的治疗方案,低血糖发生率低,尤其是对认知力较差、活动不方便、视力差或合并多种慢性病的高龄2型糖尿病患者尤为适用。Objective To investigate the efficacy and safety of insulin glargine in combination with sitagliptin on elderly patients with type 2 diabetes. Methods 78 patients （ 〉 60 yearold） were randomly divided into two groups：insulin glargine/sitagliptin combination group（ n = 40, group G）and biosynthesis premixed 30/70 insulin group （n = 38, group N）. The dose was adjusted according to blood glucose, the fasting glucose ,2 h postprandial blood glu cose, glycosylated hemoglobin（ HbA1 c） , the incidence of hypoglycemia and body mass index （BMI）after 12 weeks of treatment of the two groups were compared. Results 2 h postprandial blood glucose and the incidence of hypoglycemi a in group G were less than those in group N（P 〈0. 05）. The was no significant difference in postprandial blood glu cose, HbA1 c and BMI between the two groups （ P 〉 0.05 ）. Conclusion The treatment of insulin glargine in combina tion with sitagliptin is safe, effective and convenient for elderly patients with type 2 diabetes. This treatment program with a small incidence of hypoglycemia is very suitable for old patients with type 2 diabetes complicated with poor cog nitive activities inconvenient,poor eyesight or a variety of chronic diseases.

关 键 词：甘精胰岛素 西格列汀 老年 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]